Printer Friendly

SYSTEMIX APPOINTS NATIONAL CANCER INSTITUTE SENIOR INVESTIGATOR AS DIRECTOR OF GENE THERAPY

 PALO ALTO, Calif., Jan. 27 /PRNewswire/ -- SyStemix, Inc. (NASDAQ: STMX) today announced it has appointed National Cancer Institute (NCI) Senior Investigator James J. Mule, Ph.D, as director of gene therapy. Dr. Mule will be responsible for conceiving, initiating, designing and executing a broad scientific program to modify stem cells and to develop vehicles for gene therapy for treating infectious disease and immunocompromised patients.
 Prior to joining SyStemix, Dr. Mule, 40, spent 10 years at the NCI where he made significant contributions in gene therapy, cellular immunology and tumor immunotherapy. Dr. Mule directed the preclinical gene therapy program at the Surgery Branch, NCI. He was also a key member of the clinical research team that executed the first approved human gene therapy clinical trial as the NCI for the treatment of patients with advanced cancer. Dr. Mule has served as a consultant to Bristol-Myers Squibb, Genetics Institute and Sandoz Pharmaceutical Corp.
 "Jim is an internationally renowned expert in gene therapy, molecular biology and cell biology. His scientific accomplishments and his background in the pharmaceutical industry will be invaluable as SyStemix works to commercialize its technology," said Linda Sonntag, Ph.D, president and chief operating officer. "We look forward to having him serve as a key scientific resource for SyStemix."
 "I joined SyStemix because of its well recognized leadership and scientific excellence in human stem cell technologies. SyStemix offered the unique opportunity to rapidly bring human stem cell based therapies from the laboratory to the clinic," said Dr. Mule.
 Dr. Mule earned his Ph.D. in tumor immunology and immunopathology from the Fred Hutchinson Cancer Research Center through the University of Washington. He earned his M.S. in cellular immunology from the University of Washington School of Medicine and his B.A. in biology and radiation biology from New Jersey State College. Dr. Mule is the author of more than 150 scientific articles and is a member of the American Association of Immunologists and the American Association for Cancer research. He has won numerous awards for his work.
 SyStemix, Inc., based in Palo Alto, is primarily engaged in the development of cellular processes and products based on human hematopoietic stem cells, human megakaryocytes and megakaryocyte progenitors.
 -0- 1/27/93
 /CONTACT: Linda Sonntag, Ph.D., president & CEO of SyStemix, 415-813-6510, or Anthony J. Russo, Ph.D. of Noonan-Russo Communications, Inc., 212-979-9180/
 (STMX)


CO: SyStemix, Inc. ST: California IN: MTC SU: PER

TM -- NY009 -- 9439 01/27/93 08:31 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 27, 1993
Words:409
Previous Article:HEAD STANFORD LAWYER JOHN SCHWARTZ JOINS SYSTEMIX
Next Article:TRACER PETROLEUM CORPORATION ANNOUNCES RUSSIAN RESERVES DRILLING
Topics:


Related Articles
SYSTEMIX APPOINTS THREE SENIOR EXECUTIVES
HEAD STANFORD LAWYER JOHN SCHWARTZ JOINS SYSTEMIX
ALEXION NAMES NIH SENIOR INVESTIGATOR TO DIRECTOR OF IMMUNOBIOLOGY POST
SYSTEMIX SIGNS COLLABORATIVE AGREEMENT WITH CENTRE LEON BERARD
SYSTEMIX APPOINTS NEW VICE PRESIDENT FOR MEDICAL AFFAIRS
SYSTEMIX REPORTS SECOND QUARTER RESULTS
SYSTEMIX REPORTS SECOND QUARTER RESULTS
SYSTEMIX PHASE I/II TRIAL OF PURIFIED BLOOD CELL TRANSPLANTS SHOWS PRELIMINARY RESULTS FOR CANCER PATIENTS
SYSTEMIX' DISEASE-FREE STEM CELL TRANSPLANTS MAY CONTRIBUTE TO IMMUNE SYSTEM RECOVERY
TARGETED GENETICS NAMES BRUCE H. DEVENS DIRECTOR OF IMMUNOLOGY

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters